focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
If the UK’s anything to go by, the Ashfield partnership gives SNG the flexibility to ‘go it alone’(I doubt) or allow any JV partner to absorb the Ashfield salesforce temporarily into their own until things get up to speed post-launch.
And well-established in the UK
https://oneashfield.com/
And, perhaps, the star of the show, Prof Sir Stephen Holgate, has, as far as I’m aware made no public comment since receiving his knighthood.
But still pursuing his long held agenda against air pollution.
Cool dude.
;-)
On reflection, the FDA’s CRL letter must have been a MASSIVE shock to the company.
While I have a lot of respect for Hullihen and his team, a 12 mth delay to approval (for such a breakthrough product) will seem like a lifetime.
Tough times.
Presumably, if the company keeps buying their own shares regardless of price, the sky’s the limit and management bonuses guaranteed.
Markets don’t like uncertainty - and that’s what we have here. So, although volume traded is very low, a few ‘sells’ or ‘buys’(who knows which is which with such an unhelpful spread) will shift the sp noticeably one way or another.
I guess there’s nothing the company can say at the moment as they don’t control the newsflow.
So we wait….